Deliver Your News to the World

MYELOPEROXIDASE - A New Therapeutic Target from Lee Biosolutions


Saint Louis, MO, Lee Biosolutions,Inc has announced that it has doubled its capacity to produce Human Myeloperoxidase for the clinical diagnostic, pharmaceutical manufacturers and clinical researchers worldwide due to higher than expected demand.

Current research on this important Myeloperoxidase protein has expanded from cardivascular and stroke studies to acute lung injury, cancer, lupus and Acute lymphoblastic leukemia. Great deal of worldwide research continues with this important enzyme that Lee Biosolutions produces.

According to company President Burton Lee, Lee Biosolutions is in constant communication with its customers to determine trends and anticipate product needs before they happen. Innovative purification procedures continues to be key to the success of Lee Biosolutions business. “Myeloperoxidase has been a success story from the very beginning.”

“We understand the critical role our products play in the clinical research process”, Lee said. By maintaining higher purity and quality standards, we aim to provide clients with a wider variety of reliably consistent products which makes us the preferred producer of Myeloperoxidase products.

Lee Biosolutions Inc is a leader in the development and marketing of high valued specialty products such as Myeloperoxidase but also, recombinant proteins, coenzymes, antigens and antibodies for both research and industrial applications.

Working closely with major diagnostic companies and clinical researchers world wide in autoimmune studies, cardiovascular and cancer research, Lee Biosolutions, Inc delivers over 400 products to more than 40 countries around the globe. To learn more about how LEE BIOSOLUTIONS helps to make research work, visit



This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.